Phase 3 Randomized Trial Evaluating the Virological Efficacy and the Tolerance of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Dakar and Yaounde.

Trial Profile

Phase 3 Randomized Trial Evaluating the Virological Efficacy and the Tolerance of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Dakar and Yaounde.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2013

At a glance

  • Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lopinavir/ritonavir (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Nevirapine; Zidovudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms DAYANA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Feb 2012 Actual number of patients changed from 119 to 120 as reported by ClinicalTrials.gov.
    • 05 Aug 2011 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top